Clinical Trials
4 trialsNCT06093503 2024-06-26
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
AbbVie
Phase 3 Withdrawn
NCT05791097 2023-07-24
AdvanTIG-306
Novartis
Phase 3 Withdrawn
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT04203511 2020-06-09
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
Incyte Corporation
Phase 3 Withdrawn